MOREPEN LABORATORIES
|
MOREPEN LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.73 | 2.15 | 1.88 | 0.76 | 2.13 |
| CEPS(Rs) | 2.41 | 2.68 | 2.55 | 1.30 | 2.71 |
| DPS(Rs) | 0.20 | 0.20 | - | - | - |
| Book NAV/Share(Rs) | 22.75 | 21.10 | 16.58 | 14.73 | 11.56 |
| Tax Rate(%) | 20.24 | 23.91 | 28.65 | 30.63 | 19.75 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 6.96 | 9.61 | 9.38 | 5.61 | 8.84 |
| EBIT Margin(%) | 7.55 | 9.02 | 8.23 | 4.07 | 8.35 |
| Pre Tax Margin(%) | 6.64 | 8.56 | 8.01 | 3.93 | 8.19 |
| PAT Margin (%) | 5.30 | 6.51 | 5.72 | 2.73 | 6.57 |
| Cash Profit Margin (%) | 7.31 | 8.11 | 7.70 | 4.70 | 8.36 |
| Performance Ratios | |||||
| ROA(%) | 5.15 | 7.69 | 8.04 | 3.55 | 10.55 |
| ROE(%) | 7.96 | 11.78 | 12.08 | 5.93 | 21.79 |
| ROCE(%) | 10.19 | 15.48 | 16.82 | 8.40 | 24.86 |
| Asset Turnover(x) | 0.97 | 1.18 | 1.41 | 1.30 | 1.60 |
| Sales/Fixed Asset(x) | 2.22 | 2.50 | 2.65 | 2.23 | 2.49 |
| Working Capital/Sales(x) | 2.68 | 2.75 | 3.47 | 3.26 | 5.57 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.45 | 0.40 | 0.38 | 0.45 | 0.40 |
| Receivable days | 66.49 | 65.45 | 63.50 | 66.16 | 51.04 |
| Inventory Days | 57.79 | 55.26 | 51.55 | 64.98 | 53.23 |
| Payable days | 116.46 | 107.94 | 93.67 | 98.32 | 86.93 |
| Valuation Parameters | |||||
| PER(x) | 19.52 | 22.21 | 22.36 | 33.94 | 17.20 |
| PCE(x) | 14.02 | 17.84 | 16.53 | 19.71 | 13.52 |
| Price/Book(x) | 1.49 | 2.27 | 2.54 | 1.74 | 3.17 |
| Yield(%) | 0.59 | 0.42 | - | - | - |
| EV/Net Sales(x) | 1.10 | 1.46 | 1.26 | 0.90 | 1.11 |
| EV/Core EBITDA(x) | 13.46 | 13.78 | 12.32 | 14.96 | 10.98 |
| EV/EBIT(x) | 14.51 | 16.22 | 15.29 | 22.20 | 13.33 |
| EV/CE(x) | 1.37 | 2.15 | 2.43 | 1.65 | 1.61 |
| M Cap / Sales | 1.03 | 1.45 | 1.27 | 0.93 | 1.13 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -0.32 | 7.17 | 19.25 | -8.36 | 30.20 |
| Core EBITDA Growth(%) | -23.64 | 11.49 | 101.47 | -45.36 | 20.05 |
| EBIT Growth(%) | -16.59 | 17.49 | 140.97 | -55.29 | 28.74 |
| PAT Growth(%) | -18.95 | 22.14 | 149.82 | -61.96 | 4.73 |
| EPS Growth(%) | -19.61 | 14.50 | 148.62 | -64.44 | -1.40 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.16 | 0.07 | 0.03 | 0.03 | 0.03 |
| Current Ratio(x) | 2.37 | 2.32 | 2.21 | 2.35 | 1.61 |
| Quick Ratio(x) | 1.82 | 1.72 | 1.59 | 1.64 | 1.00 |
| Interest Cover(x) | 8.31 | 19.59 | 37.50 | 29.15 | 53.22 |
| Total Debt/Mcap(x) | 0.11 | 0.03 | 0.01 | 0.02 | 0.01 |
Compare Financial Ratios of peers of MOREPEN LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MOREPEN LABORATORIES | ₹6,754.1 Cr | -0.3% | 3.6% | 143.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹418,204.0 Cr | -1% | -5.5% | 5.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹238,497.0 Cr | -2.6% | -3.9% | 38.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹170,481.0 Cr | -1.7% | -10.2% | 30.5% | Stock Analytics | |
| CIPLA | ₹108,012.0 Cr | 0.9% | -3.2% | -15.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,207.0 Cr | -0.6% | 1% | -0.1% | Stock Analytics | |
MOREPEN LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MOREPEN LABORATORIES | -0.3% |
3.6% |
143.2% |
| SENSEX | -1.6% |
-2.3% |
-11.5% |
You may also like the below Video Courses
